Analyzing the Results of the Treating to New Targets Study

  1. Luca Mascitelli, MD; and
  2. Eddie Vos, MEng
  1. From Comando Brigata Alpina “Julia”, 33100 Udine, Italy, and Sutton, J0E 2K0 Québec, Canada.

    TO THE EDITOR:

    The analysis of the TNT trial by Wenger and colleagues (1) suggests benefit from top-dose atorvastatin in patients older than 65 years of age. However, the 22 additional deaths from noncardiovascular causes more than offset the 5 fewer deaths from cardiovascular causes (vs. patients receiving low-dose atorvastatin), a result consistent with the entire TNT study population.

    This is ominous considering that this subgroup had the following characteristics at baseline: mean age of 70 years, 82% had angina, …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med February 19, 2008 vol. 148 no. 4 321-322
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues